Most guidelines do not clearly instruct on designing toxickinetics study or inclusion of TK in a repeat dose dermal toxicity study. If TK is inlcuded, can it be justified?
Dear Laxit, knowledge on systemic exposure is an integral part of a systemic tolerance study regardless of the route of administration. After dermal application, the systemic exposure at the systemic NOAEL will be compared to the (expected or measured) human exposure after maximum clinical use to obtain the safety margin for systemic effects. To maximize systemic exposure In dermal toxicity studies in minipigs, the maximum technical feasible area dose is usually applied onto 10% body surface area (if toxicity allows). Best regards, Clemens
The reason is that toxicokinetics may give an answer to the justified question as to whether systemic uptake will take place and if so, in what quantities to estimate systemic toxicity.